5-HYDROXYTRYPTAMINE RESPONSES IN NEONATE RAT MOTONEURONS INVITRO

被引:131
作者
WANG, MY [1 ]
DUN, NJ [1 ]
机构
[1] WANNAN MED COLL,DEPT PHYSIOL,WUHU,PEOPLES R CHINA
来源
JOURNAL OF PHYSIOLOGY-LONDON | 1990年 / 430卷
关键词
D O I
10.1113/jphysiol.1990.sp018283
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
1. Current and voltage recordings were made from antidromically identified motoneurones (MNs) in transverse thoracolumbar spinal cord slices of neonatal rats. 2. Applied by superfusion (10‐100 microM) or pressure ejection, 5‐hydroxytryptamine (5‐HT) elicited a slow depolarization (or inward current) in 81% and a hyperpolarization (or outward current) in 9% of responsive MNs; the responses persisted in a low‐Ca2+, high‐Mg2+ or tetrodotoxin (TTX)‐containing solution. 3. 5‐HT induced the occurrence in some MNs of excitatory postsynaptic potentials (EPSPs) or inhibitory postsynaptic potentials (IPSPs), which were reversibly eliminated by TTX, low‐Ca2+, high‐Mg2+ solution or by the 5‐HT2 receptor antagonists ketanserin and spiperone. Also, kynurenic acid and strychnine abolished, respectively, the 5‐HT‐induced EPSPs and IPSPs. 4. The 5‐HT depolarization was associated with increased membrane resistance, was reduced by hyperpolarization and nullified near ‐100 mV. The extrapolated reversal potential was shifted to a positive direction in elevated [K+]o. 5. The depolarizing response was mimicked by the 5‐HT2 receptor agonist (+2‐)‐1(2,5‐dimethyoxy‐4‐iodophenyl)‐2‐aminopropane hydrochloride (DOI) and blocked by 5‐HT antagonists methysergide and cyproheptadine and by 5‐HT2 antagonists ketanserin and spiperone; methiothepin and MDL 72222 were without effect. 6. The 5‐HT hyperpolarization was associated with decreased membrane resistance. The 5‐HT1A agonist 8‐hydroxy‐2‐(di‐N‐propylamino) tetralin hydrobromide (8‐OH‐DPAT) mimicked the hyperpolarizing response. 7. Single or repetitive (10‐30 Hz) electrical stimuli elicited in about 30% of MNs, in addition to a fast EPSP, a slow EPSP with electrophysiological characteristics similar to that of 5‐HT induced depolarization. Methysergide and spiperone abolished the slow EPSPs evoked in some of these MNs. 8. It is suggested that 5‐HT, acting on 5‐HT2 and 5‐HT1A receptors, depolarizes and hyperpolarizes the MNs by decreasing and increasing K+ conductance. Additionally, 5‐HT activates, via 5‐HT2 receptors, excitatory and inhibitory interneurones, thereby indirectly affecting the activity of MNs. More importantly, 5‐HT released from intraspinal nerves appears to be the mediator of a slow EPSP in a population of MNs. © 1990 The Physiological Society
引用
收藏
页码:87 / 103
页数:17
相关论文
共 48 条
[1]   ANTAGONISM OF STIMULATION-PRODUCED ANALGESIA BY PARA-CPA, A SEROTONIN SYNTHESIS INHIBITOR [J].
AKIL, H ;
MAYER, DJ .
BRAIN RESEARCH, 1972, 44 (02) :692-&
[2]  
ALLMAN H, 1971, BRAIN RES, V27, P393
[3]   5-HYDROXYTRYPTAMINE RELEASE BY NERVE STIMULATION OF THE SPINAL CORD [J].
ANDEN, NE ;
CARLSSON, A ;
HILLARP, NA ;
MAGNUSSON, T .
LIFE SCIENCES, 1964, 3 (05) :473-478
[4]  
ANDERSON EG, 1966, J PHARMACOL EXP THER, V153, P352
[5]   PHARMACOLOGICALLY DISTINCT ACTIONS OF SEROTONIN ON SINGLE PYRAMIDAL NEURONS OF THE RAT HIPPOCAMPUS RECORDED INVITRO [J].
ANDRADE, R ;
NICOLL, RA .
JOURNAL OF PHYSIOLOGY-LONDON, 1987, 394 :99-124
[6]   A-G PROTEIN COUPLES SEROTONIN AND GABA-B RECEPTORS TO THE SAME CHANNELS IN HIPPOCAMPUS [J].
ANDRADE, R ;
MALENKA, RC ;
NICOLL, RA .
SCIENCE, 1986, 234 (4781) :1261-1265
[7]   MODIFICATION OF LUMBAR MOTONEURON EXCITABILITY BY STIMULATION OF A PUTATIVE 5-HYDROXYTRYPTAMINE PATHWAY [J].
BARASI, S ;
ROBERTS, MHT .
BRITISH JOURNAL OF PHARMACOLOGY, 1974, 52 (03) :339-348
[8]  
BJORKLUND A, 1971, PROGR BRAIN RES, V34, P63
[9]   ORIGINS OF SEROTONERGIC PROJECTIONS TO THE SPINAL-CORD IN RAT - AN IMMUNOCYTOCHEMICAL-RETROGRADE TRANSPORT STUDY [J].
BOWKER, RM ;
WESTLUND, KN ;
COULTER, JD .
BRAIN RESEARCH, 1981, 226 (1-2) :187-199
[10]   PROPOSALS FOR THE CLASSIFICATION AND NOMENCLATURE OF FUNCTIONAL RECEPTORS FOR 5-HYDROXYTRYPTAMINE [J].
BRADLEY, PB ;
ENGEL, G ;
FENIUK, W ;
FOZARD, JR ;
HUMPHREY, PPA ;
MIDDLEMISS, DN ;
MYLECHARANE, EJ ;
RICHARDSON, BP ;
SAXENA, PR .
NEUROPHARMACOLOGY, 1986, 25 (06) :563-576